Literature DB >> 187962

Dopaminergic stimulants and cyclic nucleotides in mouse brain. Effects of dopaminergic antagonists, cholinolytics, and GABA agonists.

S W Gumulka, V Dinnendahl, P S Schönhöfer, K Stock.   

Abstract

The effects of dopaminergic stimulants on the cyclic GMP content in the medial forebrain and the cerebellum were studied in mice pretreated with dopaminergic antagonists, cholinolytics and agents enhancing GABAergic transmission. Low doses of butyrophenones (haloperidol and spiroperidol) inhibited the rise in cyclic GMP levels and the stereotyped behaviour induced by amphetamine, but were without effect on the same biochemical and behavioural changes elicited by apomorphine. Higher doses effectively blocked the rise in cyclic GMP levels and the stereotyped behaviour elicited by both drugs. These findings suggest that low doses of the dopaminergic antagonists may predominantly act by interfering with the release of dopamine from presynaptic stores, while high doses may act by blockade of the postsynaptic dopaminergic receptor. The rise in cerebellar cyclic GMP levels elicited by dopaminergic stimulants appears not to involve cholinergic transmission, since atropine did not block the effects of the dopaminergic stimulants. Enhancement of GABAergic transmission by diazepam or aminooxyacetic acid antagonized the rise in cerebellar cyclic GMP content induced by the dopaminergic stimulants, but was without effect on the cyclic GMP content in the medial forebrain. Cyclic AMP levels were not affected by any of the drugs in both parts of the brain.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 187962     DOI: 10.1007/bf00509767

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  19 in total

Review 1.  New concepts on the mechanism of action of benzodiazepines.

Authors:  E Costa; A Guidotti; C C Mao; A Suria
Journal:  Life Sci       Date:  1975-07-15       Impact factor: 5.037

2.  Effects of stress on mouse brain cyclic nucleotide levels in vivo.

Authors:  V Dinnendahl
Journal:  Brain Res       Date:  1975-12-26       Impact factor: 3.252

3.  Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons.

Authors:  N E Andén; H Corrodi; K Fuxe; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1971-07       Impact factor: 4.432

4.  A rapid and simple procedure for the determination of guanosine 3',5'-monophosphate by use of the protein-binding method.

Authors:  V Dinnendahl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

5.  Evidence for dopamine receptor stimulation by apomorphine.

Authors:  N E Andén; A Rubenson; K Fuxe; T Hökfelt
Journal:  J Pharm Pharmacol       Date:  1967-09       Impact factor: 3.765

6.  Stereotaxic mapping of the monoamine pathways in the rat brain.

Authors:  U Ungerstedt
Journal:  Acta Physiol Scand Suppl       Date:  1971

7.  On the mode of action of apomorphine.

Authors:  B Costall; R J Naylor
Journal:  Eur J Pharmacol       Date:  1973-03       Impact factor: 4.432

8.  Reduction of level of L-glutamic acid decarboxylase by gamma-aminobutyric acid in mouse brain.

Authors:  P Y Sze; R A Lovell
Journal:  J Neurochem       Date:  1970-12       Impact factor: 5.372

9.  Effects of dopaminergic stimulants on cyclic nucleotide levels in mouse brain in vivo.

Authors:  S W Gumulka; V Dinnendahl; H D Peters; P S Schönhöfer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

10.  Effects of stimulatory and depressant drugs on cyclic guanosine 3',5'-monophosphate and adenosine 3',5'-monophosphate levels in mouse brain.

Authors:  F A Opmeer; S W Gumulka; V Dinnedahl; P S Schönhöfer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

View more
  1 in total

1.  On the mode of action of clonidine: relationship between effects on behaviour and cyclic nucleotide content in mouse brain.

Authors:  S W Gumulka; V Dinnendahl; D Bartmus; P S Schönhöfer; K Stock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-05       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.